Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568854 · ClinicalTrials.gov registry record · NA
Immunobiology of Diabetes and Tuberculosis
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00568854: Clinical Trial NA study, sponsored by Stanford University.
NCT00568854 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568854, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study hypothesis is that type 2 diabetics have abnormal cell-mediated immunity to tuberculosis manifesting as altered cytokine responses by peripheral blood mononuclear cells (PBMCs). This hypothesis will be tested using the live tuberculosis vaccine, Bacille Calmette-Guerin (BCG), in U.S.-born type 2 diabetics and nondiabetics. The investigators will control for potential confounding by age, sex, race, comorbidities, and select medications. Expression of key cytokines will be measured with real-time polymerase chain reaction.
Interventions
- BIOLOGICAL BCG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568854
The ClinicalTrials.gov registry entry for NCT00568854 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BCG is the first listed.
NCT00568854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00568854 about?
NCT00568854 is a clinical study titled "Immunobiology of Diabetes and Tuberculosis". The study hypothesis is that type 2 diabetics have abnormal cell-mediated immunity to tuberculosis manifesting as altered cytokine responses by peripheral blood mononuclear cells (PBMCs). This hypothesis will be tested using the live tuberculosis vaccine, Bacille Calmette-Guerin (BCG), in U.S.-born ...
What is the current status of trial NCT00568854?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00568854?
The interventions under investigation include: BCG (BIOLOGICAL).
Who is sponsoring clinical trial NCT00568854?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.